Webb17 juni 2024 · (RTTNews) - ObsEva SA (OBSV) said Friday that the European Commission has granted marketing authorization for Yselty (linzagolix), an oral GnRH antagonist, for the management of moderate to... http://www.theramex.com/
ObsEva Announces UK MHRA Marketing Authorization for Yselty ...
Webb23 aug. 2024 · Linzagolix (Yselty ®) is an orally administered, selective, non-peptide small molecule gonadotrophin releasing hormone (GnRH) receptor antagonist that is being developed by Kissei Pharmaceutical for the treatment of uterine fibroids and endometriosis in women of reproductive age.Linzagolix binds to and blocks the GnRH receptor in the … Webb17 juni 2024 · The European Commission (EC) has granted Marketing Authorization for Yselty® (linzagolix), an oral GnRH antagonist, indicated for the treatment of moderate to … song abilene written by
ObsEva Announces European Commission Marketing
WebbYselty® (linzagolix, previously known as OBE2109) is a novel, oral, once daily, GnRH receptor antagonist with a potentially best-in-class profile. Yselty is currently in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. WebbTheramex has 5 employees across 8 locations. See insights on Theramex including office locations, competitors, revenue, financials, executives, ... Theramex Announces European Commission Marketing Authorization for Yselty® (linzagolix), an Oral GnRH Antagonist, for the treatment of symptoms of Uterine Fibroids. Jun 17, 2024. Theramex UK Stock ... Webb17 juni 2024 · -Yselty® (linzagolix) is the first and only approved GnRH antagonist to provide flexible dosing options with and without hormonal add-back therapy- -Theramex to commercialize Yselty®; ObsEva to receive royalties on commercial sales, as well as development, commercial, and sales-based milestone payments- small dog fence outdoor